ArticleWorld journal of hepatology2025
Clinical characteristics of patients with hepatitis and cirrhosis and the construction of a prediction model.
Article in World journal of hepatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHepatitis B-associated cirrhosis is an important disease burden in China. However, there is a lack of effective predictors in clinical practice to drive delivery and enable early treatment to delay disease progression.
aimTo analyzing the clinical characteristics of patients with hepatitis and cirrhosis, the nomogram model was established and validated.
methodsThe clinical data of 1070 patients with hepatitis B who were treated in our hospital from October 2015 to July 2022 were collected. In a 7:3 ratio, 749 cases were divided into training cohorts and 321 cases were divided into validation cohorts. In addition, the training cohort and validation cohort were further divided into hepatitis group and hepatitis B-related cirrhosis group based on whether the patient progressed to cirrhosis. Binary logistic regression was used to analyze the influencing factors of hepatitis progression to cirrhosis. A roadmap prediction model was established, and the predictive effect of the model was evaluated by patient-subject receiver operating characteristic curve (ROC), and the effectiveness of the model was evaluated by decision curve analysis.
resultsBinary logistic regression analysis was performed using hepatitis B-related cirrhosis = 1 and hepatitis = 0 as dependent variables, and univariate analysis of serological indicators was used as covariates. The results showed that glutamic oxaloacetate aminotransferase/glutamate acetone aminotransferase levels, prothrombin time activity, and hepatitis B e antigen levels were all contributing factors to the progression of hepatitis to cirrhosis. The area under the ROC curve was 0.693 [95% confidence interval (CI): 0.631 to 0.756] for the training cohort and 0.675 (95%CI: 0.561 to 0.790) for the validation cohort. In addition, the decision analysis curves of the prediction models of both the training cohort and the validation cohort confirmed the effectiveness of the nomogram prediction model.
conclusionThree independent factors influencing the progression to cirrhosis in patients with hepatitis B were identified. The construction of a nomogram prediction model from hepatitis to cirrhosis has high application value as a tool for predicting the occurrence of liver cirrhosis in hepatitis B patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.